Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMOGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $5.67.

SGMO has been the topic of a number of research analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. StockNews.com initiated coverage on Sangamo Therapeutics in a research report on Thursday. They set a “sell” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday, May 15th.

Get Our Latest Analysis on Sangamo Therapeutics

Sangamo Therapeutics Stock Performance

SGMO stock opened at $0.32 on Friday. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.67. The firm has a market cap of $66.92 million, a P/E ratio of -0.17 and a beta of 1.24. The business’s 50 day moving average is $0.52 and its 200-day moving average is $0.61.

Sangamo Therapeutics (NASDAQ:SGMOGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The company had revenue of $0.48 million during the quarter, compared to the consensus estimate of $8.51 million. During the same quarter in the prior year, the company posted $0.12 earnings per share. Sell-side analysts forecast that Sangamo Therapeutics will post -0.55 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SGMO. SG Americas Securities LLC lifted its holdings in Sangamo Therapeutics by 103.9% during the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 92,002 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 129,811 shares in the last quarter. Mackenzie Financial Corp lifted its stake in shares of Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 31,003 shares during the period. Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 21.0% in the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 34,960 shares during the period. Finally, Wasatch Advisors LP lifted its stake in shares of Sangamo Therapeutics by 62.4% in the 1st quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

(Get Free Report

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Read More

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.